Cargando…

The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy

OBJECTIVES: The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adamczyk, Bożena, Wawrzyniak, Sławomir, Kasperczyk, Sławomir, Adamczyk-Sowa, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613460/ https://www.ncbi.nlm.nih.gov/pubmed/29138683 http://dx.doi.org/10.1155/2017/9625806

Ejemplares similares

Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches
por: Niedziela, Natalia, et al.
Publicado: (2016)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
por: Jamroz-Wiśniewska, Anna, et al.
Publicado: (2021)

Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment
por: Bartosik-Psujek, Halina, et al.
Publicado: (2023)

Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients
por: Adamczyk-Sowa, Monika, et al.
Publicado: (2016)

Significance of the Diagnosis of Executive Functions in Patients with Relapsing-Remitting Multiple Sclerosis
por: Borkowska, Aneta R., et al.
Publicado: (2021)

New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis
por: Adamczyk, Bożena, et al.
Publicado: (2016)

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
por: Bizoń, Anna, et al.
Publicado: (2022)

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
por: Mezei, Zsolt, et al.
Publicado: (2012)

Month of birth and level of insolation as risk factors for multiple sclerosis in Poland
por: Dobrakowski, Paweł, et al.
Publicado: (2017)

The influence of sodium on pathophysiology of multiple sclerosis
por: Zostawa, Jacek, et al.
Publicado: (2017)

LINE-1 Hypermethylation in Serum Cell-Free DNA of Relapsing Remitting Multiple Sclerosis Patients
por: Dunaeva, Marina, et al.
Publicado: (2017)

Serum Levels of Anti-Myelin Antibodies in Relapsing-Remitting Multiple Sclerosis Patients during Different Phases of Disease Activity and Immunomodulatory Therapy
por: Angelucci, Francesco, et al.
Publicado: (2005)

Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing–Remitting Multiple Sclerosis
por: Bizoń, Anna, et al.
Publicado: (2023)

Multiple sclerosis patients and COVID-19
por: Mado, Hubert, et al.
Publicado: (2021)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
por: Sips, Fianne L. P., et al.
Publicado: (2022)

Oxidative Stress is Increased in Serum from Mexican Patients with Relapsing-Remitting Multiple Sclerosis
por: Ortiz, Genaro Gabriel, et al.
Publicado: (2009)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

The course of COVID-19 infection in patients with multiple sclerosis–The experience of one center based on the population of Upper Silesia
por: Nowak-Kiczmer, Maria, et al.
Publicado: (2021)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment
por: Adamczyk-Sowa, Monika, et al.
Publicado: (2017)

Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data
por: Bell, Christopher, et al.
Publicado: (2007)

Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
por: Mado, Hubert, et al.
Publicado: (2021)

Correction: oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
Publicado: (2019)

The Rate of Hospitalization of Pregnant Women with Multiple Sclerosis in Poland
por: Walkiewicz, Dorota, et al.
Publicado: (2022)

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients
por: Vázquez-Marrufo, Manuel, et al.
Publicado: (2019)

Evidence of Autonomic Dysfunction in Patients with Relapsing-Remitting Multiple Sclerosis: Heart Rate Variability and Cardiovascular Parameters
por: Gerasimova-Meigal, Liudmila, et al.
Publicado: (2021)

COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience
por: Preziosa, Paolo, et al.
Publicado: (2020)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tpso2dv46ts94kt5kv8l8rt779